20397-59-5Relevant articles and documents
Cis-cinnamic acid analogue, gravitropism modifier (by machine translation)
-
Paragraph 0127-0128, (2019/11/30)
[Problem] cinnamic acid or cinnamic acid analogue comprising adjusting agent gravitropism cis. [Solution] cinnamic acid and/or cinnamic acid as an active ingredient to adjust gravitropism cis edge agents, cinnamic acid edge is, for example obtained by reacting compounds of the following formula. (In the formula, R is a phenyl group. )Figure 6 [drawing] (by machine translation)
Effect of Fluorination on Skin Sensitization Potential and Fragrant Properties of Cinnamyl Compounds
Charpentier, Julie,Emter, Roger,Koch, Heinz,Lelièvre, Dominique,Pannecoucke, Xavier,Couve-Bonnaire, Samuel,Natsch, Andreas,Bombrun, Agnes
, (2018/04/27)
A series of three α- and three β-fluorinated representatives of the family of cinnamate-derived odorants (cinnamaldehyde (1), cinnamyl alcohol (2), and ethyl cinnamate (3)) as used as fragrance ingredients is described. Olfactive evaluation shows that the
Development of the First Two-Pore Domain Potassium Channel TWIK-Related K+ Channel 1-Selective Agonist Possessing in Vivo Antinociceptive Activity
Vivier, Delphine,Soussia, Ismail Ben,Rodrigues, Nuno,Lolignier, Stéphane,Devilliers, Ma?ly,Chatelain, Franck C.,Prival, Laetitia,Chapuy, Eric,Bourdier, Geoffrey,Bennis, Khalil,Lesage, Florian,Eschalier, Alain,Busserolles, Jér?me,Ducki, Sylvie
, p. 1076 - 1088 (2017/02/19)
The TWIK-related K+ channel, TREK-1, has recently emerged as an attractive therapeutic target for the development of a novel class of analgesic drugs, suggesting that activation of TREK-1 could result in pain inhibition. Here, we report the synthesis of a series of substituted acrylic acids (1-54) based on our previous work with caffeate esters. The analogues were evaluated for their ability to modulate TREK-1 channel by electrophysiology and for their in vivo antinociceptive activity (acetic acid-induced writhing and hot plate assays), leading to the identification of a series of novel molecules able to activate TREK-1 and displaying potent antinociceptive activity in vivo. Furyl analogue 36 is the most promising of the series.